The global market for minimally invasive glaucoma surgery (MIGS) devices is projected to increase from about $540 million in 2023 to exceed $780 million by 2030, according to a recent report by Research and Markets. According to the company’s projections, MIGS device sales will grow at a compound annual growth rate (CAGR) of roughly 5.4% between 2024 and 2030.

Research and Markets found that glaucoma drainage implants were the most used MIGS devices in 2023, with a revenue share of over 33%. Based on surgery method, the trabecular meshwork bypass segment held the largest market share in 2023. North America was the largest market for MIGS device sales, with a revenue share above 35% in 2023.

According to the report, factors propelling market growth over the next six years include greater awareness about MIGS, technological advancements, the expanding geriatric population, and the continuous development of healthcare infrastructure. Healthcare professionals increasingly prefer minimally invasive surgeries since they offer advantages such as smaller incisions, rapid wound healing, reduced pain, and smaller or no surgical scars.